← Tarsus Pharmaceuticals, Inc.
| Annual Trend | FY 2019 | FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | TTM | |
|---|---|---|---|---|---|---|---|---|---|
| Net loss | ($4.7m) | ($26.8m) | ($13.8m) | ($62.1m) | ($135.9m) | ($115.6m) | ($66.4m) | — | |
| Depreciation | $37k | $96k | $312k | $325k | $744k | $685k | $855k | $1.4m | |
| Amortization of intangible assets | — | — | — | $0 | $133k | $540k | $961k | — | |
| Amortization/accretion of debt-related costs | — | — | $0 | $309k | $385k | $482k | $593k | — | |
| Net amortization/accretion on marketable securities | — | — | $0 | ($1.3m) | ($3.2m) | ($4.2m) | ($5.5m) | — | |
| Stock-based compensation | $18k | $839k | $8.5m | $13.5m | $19.8m | $27.8m | $41.7m | $51.8m | |
| Realized/unrealized loss (gain) on equity investments | — | — | — | $268k | ($259k) | $591k | $0 | — | |
| Accounts receivable, net | — | — | — | $0 | ($16.6m) | ($30.1m) | ($38.3m) | ($38.0m) | |
| Other receivables | ($32k) | $16k | ($73k) | ($3.5m) | $2.5m | ($206k) | ($754k) | — | |
| Inventory | — | — | — | $0 | ($3.1m) | ($2.0m) | ($1.8m) | ($497k) | |
| Accounts payable | $245k | $3.2m | $3.9m | $821k | $13.2m | $40.3m | $6.9m | $30.0m | |
| Additions of property and equipment included within accounts payable and other accrued liabilities | $10k | $34k | $2k | $21k | $134k | $99k | $1.5m | — | |
| Offering costs included within accounts payable | — | — | — | $0 | $0 | $21k | $0 | — | |
| Accrued payroll and benefits | $296k | $741k | $1.8m | $2.7m | $7.7m | $2.6m | $2.0m | — | |
| Other accrued liabilities | — | — | — | — | $8.7m | $37.8m | $45.4m | — | |
| Net cash used in operating activities | ($3.7m) |
($21.1m)
-475.50%
|
$3.7m
+117.73%
|
($49.0m)
-1408.16%
|
($117.5m)
-139.63%
|
($83.0m)
+29.33%
|
($12.5m)
+85.00%
|
$74.2m
+695.60%
|
|
| Purchases of property and equipment | ($175k) | ($456k) | ($586k) | ($506k) | ($1.5m) | ($1.6m) | ($9.9m) | ($18.2m) | |
| Proceeds from sales and maturities of marketable securities | — | — | — | $5.3m | $174.8m | $73.0m | $361.8m | — | |
| Purchases of marketable securities | — | — | $0 | ($149.4m) | ($28.7m) | ($262.6m) | ($393.2m) | — | |
| Purchases of long-term investments | — | — | — | $0 | $0 | ($3.0m) | ($870k) | — | |
| Net cash (used in) provided by investing activities | ($175k) | ($456k) | ($586k) | ($144.6m) | $140.6m | ($199.2m) | ($42.1m) | — | |
| Loss on debt extinguishment | $255k | $0 | — | $0 | $0 | $1.9m | $0 | — | |
| Proceeds from long-term debt | — | — | — | $20.0m | $10.0m | $75.0m | $0 | — | |
| Payment of debt issuance costs | — | — | $0 | ($875k) | $0 | ($3.5m) | $0 | — | |
| Payments for debt extinguishment | — | — | — | $0 | $0 | ($31.9m) | $0 | — | |
| Proceeds from issuance of common stock, net of paid issuance costs | — | — | — | $74.4m | $118.6m | $98.3m | $134.8m | $0 | |
| Proceeds from sale of common stock under employee stock purchase plan | — | $0 | $221k | $462k | $985k | $1.8m | $2.3m | — | |
| Net cash provided by financing activities | $59.4m |
$131.8m
+121.67%
|
$21k
-99.98%
|
$94.0m
+447457.14%
|
$130.2m
+38.50%
|
$154.7m
+18.81%
|
$143.4m
-7.29%
|
$9.4m
-93.46%
|
|
| Net increase (decrease) in cash, cash equivalents and restricted cash | $55.6m | $110.2m | $3.2m | ($99.7m) | $153.3m | ($127.6m) | $88.8m | — | |
| Cash, cash equivalents and restricted cash at beginning of period | $58.0m | $168.1m | $171.3m | $71.7m | $224.9m | $97.4m | $186.2m | — | |
| Additional Supplementary Disclosures | |||||||||
| Additional Supplementary Disclosures | |||||||||
| Non-cash lease expense | — | $150k | $294k | $464k | $541k | $635k | $682k | — | |
| Change in fair value of equity warrants issued by licensee | $76k | $0 | $987k | $501k | ($117k) | $201k | $0 | — | |
| Prepaid expenses | — | — | ($2.0m) | ($721k) | ($2.9m) | ($7.0m) | $1.7m | — | |
| Other non-current assets | ($6k) | ($75k) | ($2.3m) | ($215k) | ($718k) | $572k | ($527k) | — | |
| Other long-term liabilities | — | $0 | $115k | ($67k) | $185k | ($233k) | $0 | — | |
| Intangible asset additions | — | — | — | $0 | ($4.0m) | ($5.0m) | $0 | — | |
| Proceeds from issuance of pre-funded warrants, net of paid issuance costs | — | — | — | $0 | $0 | $9.4m | $0 | — | |
| Proceeds from exercise of stock options | — | $10k | $103k | $123k | $592k | $5.6m | $6.3m | — | |
| Operating lease right-of-use asset obtained in exchange for operating lease liability | $163k | $726k | $741k | $0 | $1.8m | $384k | $10.2m | — | |
| Operating lease modification | — | — | — | $0 | $0 | $1.1m | $0 | — | |
| Interest expense paid in cash | — | — | $0 | $1.7m | $2.9m | $7.7m | $8.3m | — |